Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228369 · ClinicalTrials.gov registry record · Phase 1
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT02228369 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 108 participants.
The verdict
NCT02228369, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis and Brain Metastasis may also be enrolled to assess the anti-tumour efficacy, safety, pharmacokinetics and potential biological activity of AZD9291
Interventions
- DRUG AZD9291
- DRUG AZD3759
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2014-11-05 |
| Est. Completion | 2020-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228369
The ClinicalTrials.gov registry entry for NCT02228369 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD9291 is the first listed.
NCT02228369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228369 about?
NCT02228369 is a clinical study titled "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer". This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis and Brain Metastasis may also be enrolled to assess the anti-tumour effic...
What is the current status of trial NCT02228369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2014-11-05. Estimated completion is 2020-10-28.
What interventions are being tested in trial NCT02228369?
The interventions under investigation include: AZD9291 (DRUG), AZD3759 (DRUG).
Who is sponsoring clinical trial NCT02228369?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.